Text Size:

Stage 4: Metastatic Prostate Cancer

Comprehensive information about Stage 4 prostate cancer, treatment approaches, and support resources for patients and families in New Zealand.

Approximately 8% of men in New Zealand are diagnosed with Stage 4 prostate cancer, called "de novo" metastatic disease.

The 5-year survival rate for metastatic prostate cancer is around 30%, though newer treatments are improving these outcomes.

In New Zealand, approximately 350 men are diagnosed with de novo Stage 4 prostate cancer annually.

About 63% of patients with metastatic prostate cancer in New Zealand receive hormone therapy (ADT) as their primary treatment.

Stage 4 prostate cancer means the cancer has spread beyond the prostate to distant parts of the body. At this stage:

  • The cancer has metastasized to other organs, lymph nodes, or bones
  • PSA levels are typically very elevated
  • The Gleason score is usually 8-10

Stage 4 is further divided into:

  • Stage 4A: Cancer has spread to nearby lymph nodes but not to distant organs
  • Stage 4B: Cancer has spread to distant lymph nodes, bones, or other organs

In New Zealand, approximately 8% of prostate cancer diagnoses are metastatic (Stage 4) at the time of diagnosis. This equates to about 350 men annually diagnosed with what doctors call "de novo" metastatic disease, meaning they are diagnosed at Stage 4 without having gone through earlier stages.

While Stage 4 prostate cancer is not typically curable, many men live for years with good quality of life with proper treatment and management.

Explore Cancer Stages